光动力疗法联合异维A酸治疗中重度痤疮的疗效

目的:探讨光动力疗法(PDT)联合口服异维A酸治疗面部中重度痤疮的疗效及安全性。方法:2018年1—6月,吉林大学中日联谊医院皮肤科将中重度痤疮患者90例[男42例,女48例;年龄18~35(23.98±4.25)岁]分为PDT联合异维A酸组(联合组)、PDT组、异维A酸组,每组30例。治疗10、20、30 d记录患者...     

异维A酸联合丹参酮胶囊短期治疗中度寻常性痤疮疗效观察

目的:观察异维A酸联合丹参酮胶囊短期治疗中度寻常性痤疮的疗效。方法:将患者随机分为两组,治疗组:口服异维A酸10mg,2次/天,4周后减为10mg,每晚1次,丹参酮胶囊1.0,3次/天;对照组:外擦1%克林霉素磷酸脂溶液,2次/天。共治疗8周。结果:治疗组有效率为82.1%,对照组有效率为37.9%,两组疗效比较,差异有统计学意义(χ2=11.6,P0.01)。结论:异维A酸联合丹参酮胶囊短期治疗中度寻常性痤疮安全、疗效好。     

口服异维A酸联合光动力治疗重度痤疮疗效分析

目的:探讨异维A酸联合光动力治疗(Photodynamic therapy,PDT)重度痤疮的临床效果.方法:选取2017年2月-2019年4月笔者医院皮肤科收治的80例重度痤疮患者,随机分为对照组和研究组,每组40例,其中对照组采用光动力疗法,研究组在对照组基础上采用异维A酸进行治疗,两组均治疗4周,随访3个月,比较...     

光动力疗法联合口服异维A酸治疗中重度痤疮的临床疗效及安全性分析

目的：探讨光动力疗法联合口服异维A酸治疗中重度痤疮的临床疗效及安全性。方法：纳入2020年6月-2022年6月笔者医院收治的中重度痤疮患者84例,随机分为异维A酸组、光疗组和联合治疗组,各28例。异维A酸组予以口服异维A酸治疗,光疗组予以光动力疗法,联合治疗组予以光动力疗法联合口服异维A酸治疗,评估三组治疗效果,观察治疗前及治疗8周后患者皮损数量及生活质量,记录治疗期间不良反应。结果：联合治疗组总有效率（82.14%）显著高于异维A酸组（46.43%）和光疗组（57.14%）（均P<0.05）。治疗后,联合治疗组非炎性皮损数量显著低于异维A酸组和光疗组（P<0.05）,联合治疗组和光疗组治疗后炎性皮损数量显著低于异维A酸组（P<0.05）。治疗后,三组患者Acne-Qol各维度评分较治疗前均有明显上升（P<0.05）,且联合治疗组明显高于异维A酸组和光疗组（P<0.05）。联合治疗组和光疗组患者的红斑水肿、反应性痤疮、色素沉着发生率均高于异维A酸组（P<0.05）,三组间干燥脱屑比较差异无统计学意义（P>0.05）。结论：光动力疗法联合口服异维...     

异维A酸红霉素凝胶治疗寻常性痤疮临床观察

目的：评价异维A酸红霉素凝胶治疗轻、中度寻常性痤疮的有效性及安全性。方法：采用随机开放对照研究,把100例轻、中度寻常性痤疮患者随机分为治疗组和对照组（各50例）,分别应用异维A酸红霉素凝胶（治疗组）、复方维A酸凝胶（对照组）外涂痤疮皮损,按1次/天×8w方案,在治疗前、治疗2、4、8w随访观察,对其疗效和不良反应等记录,进行统计学分析。结果：91例患者完成治疗随访（治疗组44例,对照组45例）,失访11例（治疗组5例,对照组6例）。治疗8w后,异维A酸红霉素凝胶组临床治愈率和有效率明显高于复方维A酸凝胶组,差异具有统计学意义（P〈0.05）,且无严重不良反应。结论：异维A酸红霉素凝胶治疗轻、中度寻常性痤疮安全,疗效满意。     

异维A酸胶囊间歇给药治疗中重度痤疮的临床效果

探讨中重度痤疮患者应用异维A酸胶囊间歇给药治疗的效果。方法 选取青县人民医院皮肤 科2022年5月-2023年5月收治的60例中重度痤疮患者为研究对象，采用随机数字表法分为对照组和观察 组，各30例。对照组予以异维A酸胶囊传统每日疗法治疗，观察组予以异维A酸胶囊间歇疗法治疗，比 较两组临床疗效及不良反应发生情况。结果 观察组治疗总有效率为90.00%，高于对照组的83.33%， 但差异无统计学意义（P ＞0.05）；观察组不良反应发生率为3.33%，低于对照组的26.67%，差异有统 计学意义（P ＜0.05）。结论 中重度痤疮患者应用传统每日疗法和间歇疗法给予异维A酸胶囊治疗效果相 当，但间歇疗法给药可降低不良反应发生几率，值得临床应用。     

艾拉光动力联合异维A酸软胶囊治疗结节囊肿型痤疮的疗效

目的 探究结节囊肿型痤疮行艾拉光动力联合异维A酸软胶囊治疗的临床效果。方法 选取2022年 1月-2023年1月六盘水市钟山区人民医院皮肤科收治的40例结节囊肿型痤疮患者为研究对象,采用随机数 字表法分为参考组和试验组,各20例。参考组使用抗生素联合异维A酸软胶囊治疗,试验组采取艾拉光 动力联合异维A酸软胶囊治疗,比较两组临床疗效、不良反应发生率以及疾病复发率。结果 试验组治疗 总有效率为95.00%,高于参考组的60.00%（P ＜0.05）;试验组不良反应发生率为10.00%,低于参考组的 35.00%（P＜0.05）;试验组疾病复发率为5.00%,低于参考组的30.00%（P＜0.05）。结论 艾拉光动力联合 异维A酸软胶囊治疗结节囊肿型痤疮的效果确切,能够提高临床疗效,降低不良反应发生率,减少疾病复 发,值得临床借鉴     

异维A酸用于中度寻常痤疮的治疗效果

探究异维A酸用于治疗中度寻常痤疮的临床效果。方法 选取渭南市临渭区中医医院2019年8月-2020年8月收治的80例中度寻常痤疮患者为研究对象,根据患者所用治疗方案的不同分为参照组和观察组,每组40例。参照组采用他扎罗汀乳膏进行治疗,观察组采用异维A酸红霉素凝胶进行治疗,比较两组治疗后的皮损情况、临床疗效及不良反应发生情况。结果 观察组治疗后皮损情况优于参照组（P ＜0.05）;观察组临床治疗总有效率为97.50%,高于参照组的80.00%（P ＜0.05）;观察组不良反应发生率为0,低于参照组的12.50%（P ＜0.05）。结论 异维A酸能够改善患者皮损情况,提高临床治疗总有效率,减少不良反应的发生。     

光动力学疗法治疗寻常性痤疮研究进展

寻常性痤疮是一种毛囊、皮脂腺的慢性炎症性皮肤病。好发于颜面及胸背部,多发于青年人,痤疮不仅造成皮损局部不适,更重要的因影响容貌而对患者造成心理损害。依据皮损性质和严重程度痤疮分为三度4级:Ⅰ级(轻度):仅有粉刺;Ⅱ级(中度):Ⅰ级基础上出现炎性丘疹;Ⅲ级(中度):Ⅱ级基础上出现脓疱;Ⅳ级(重度):Ⅲ级基础上出现结节、囊肿或瘢痕。     

口服异维 A 酸与臭氧液体敷料联合治疗寻常痤疮患者的效果

目的 探究口服异维A酸与臭氧液体敷料联合治疗寻常痤疮患者的临床效果。方法 选取2021年 1月-2021年12月于我院就诊的62例寻常痤疮患者作为研究对象,采用随机数字表法分为观察组和对照组, 各31例。对照组予以异维A酸胶囊口服治疗,观察组在对照组基础上加臭氧液体敷料联合治疗,比较两组 皮脂溢出情况、临床疗效、炎症因子水平以及复发率。结果 观察组治疗总有效率为93.55%,高于对照组的 74.19%,差异有统计学意义（P＜0.05）;观察组皮疹消退率高于对照组,差异有统计学意义（P＜0.05）; 观察组治疗后TNF-α、IL-1β、IL-6均低于对照组,差异有统计学意义（P＜0.05）;观察组复发率为 3.23%,低于对照组的19.35%,差异有统计学意义（P＜0.05）。结论 口服异维A酸联合臭氧液体敷料治疗 寻常痤疮患者可有效改善患者皮损症状,降低炎症因子水平和复发率,值得临床应用。     

Light Therapy in the Treatment of Acne Vulgaris

Background. Over the past decade, lasers and light-based systems have become a common modality to treat a wide variety of skin-related conditions, including acne vulgaris. In spite of the various oral and topical treatments available for the treatment of acne, many patients fail to respond adequately or may develop side effects. Therefore, there is a growing demand by patients for a fast, safe, and side-effect–free novel therapy.
Objectives. To address the role of light therapy in the armamentarium of treatments for acne vulgaris, to discuss photobiology aspects and biomedical optics, to review current technologies of laser/light-based devices, to review the clinical experience and results, and to outline clinical guidelines and treatment considerations.
Results. Clinical trials show that 85% of the patients demonstrate a significant quantitative reduction in at least 50% of the lesions after four biweekly treatments. In approximately 20% of the cases, acne eradication may reach 90%. At 3 months after the last treatment, clearance is approximately 70% to 80%. The nonrespondent rate is 15% to 20%.
Conclusions. Laser and light-based therapy is a safe and effective modality for the treatment of mild to moderate inflammatory acne vulgaris. Amelioration of acne by light therapy, although comparable to the effects of oral antibiotics, offers faster resolution and fewer side effects and leads to patient satisfaction.     

Oral Zinc as a Novel Adjuvant and Sparing Therapy for Systemic Isotretinoin in Acne Vulgaris: A Preliminary Comparative Study

BackgroundSystemic isotretinoin is the most effective treatment for acne vulgaris (AV). However, numerous side effects are associated with isotretinoin. Oral zinc has a better safety profile and has been used to treat AV with variable results. ObjectiveWe sought to evaluate the safety and efficacy of combining oral zinc to low-dose systemic isotretinoin in AV patients.MethodsSixty AV patients were divided into two groups. Group A received oral zinc sulfate plus low-dose isotretinoin and Group B received the standard isotretinoin dosage. At each visit acne severity, photos, side effects, and patient-reported satisfaction were recorded.ResultsIn the two groups, no significant difference in reduction of lesion count and Global Acne Grading System scores. The frequency of treatment-related side effects was (20%) in Group A and (76.7%) in Group B. Furthermore, there was no difference regarding the relapse rates between both groups (p>0.05). Finally, the patients’ satisfaction rates did not differ between the two groups.ConclusionOral zinc plus low-dose isotretinoin resulted in satisfactory improvement in AV patients with fewer side effects. Further studies are recommended to compare the efficacy of other zinc preparations if combined with systemic isotretinoin at different concentrations.     

Anti-androgenic Therapy Using Oral Spironolactone for Acne Vulgaris in Asians

Background Few studies have addressed anti-androgenic therapy using oral spironolactone for acne in Asians. Obtaining this race-specific information is important because Westerners and Asians respond differently to hormone therapy. This study aimed to examine the efficacy and safety of oral spironolactone used to treat acne in Asians. Methods Spironolactone (initial dose, 200 mg/day) was administered orally to 139 Japanese patients (116 females and 23 males) with acne. Serum laboratory data, including various hormones and electrolytes, were examined for 25 of the subjects. Results Most of the female patients who completed the 20-week regimen exhibited excellent improvement (evaluated by a photographic grading scale), although some discontinued treatment because of menstrual disturbances or other reasons. The treatment was less efficacious for the males than for the females, and because gynecomastia developed in three male patients, spironolactone treatment for males was stopped. Examination of the serum of 25 patients did not identify any toxicity associated with the treatment. Drug eruptions and edema in the lower extremities were each seen in three patients. Conclusion Oral spironolactone is effective and safe for the treatment of acne in Asian females, and can be a good option for severe, recurring, and widespread types of the condition.     

果酸联合粉刺挤压术治疗寻常痤疮的疗效

目的 研究果酸联合粉刺挤压术治疗寻常痤疮的疗效。方法 选取2021年3月-10月东莞市滨海湾中心医院接诊的寻常痤疮患者268例为研究对象,按照随机数字表法分成对照组和联合组,各134例。对照组予以果酸焕肤治疗,联合组在对照组治疗基础上联合粉刺挤压术,比较两组痤疮综合分级、临床疗效及不良反应发生情况。结果 联合组治疗第2、3、4次痤疮综合分级评分低于治疗前、治疗第1次及对照组,差异有统计学意义（P＜0.05）;联合组治疗总有效率高于对照组,差异有统计学意义（P＜0.05）;两组不良反应发生率比较,差异无统计学意义（P＞0.05）。结论 果酸联合粉刺挤压术治疗寻常痤疮效果确切,可改善痤疮程度,且治疗安全性较高。     

Efficacy and Tolerability of HydraFacial Clarifying Treatment Series in the Treatment of Active Acne Vulgaris

ObjectiveThis 12-week, multicenter, open-label study investigated the efficacy and tolerability of the HydraFacial Clarifying Treatment for improving skin appearance in patients who present with acne vulgaris.MethodsTwenty eligible adult patients with mild-to-moderate acne were enrolled at one of two treatment sites in the United States and were to undergo six HydraFacial Clarifying Treatments, one every two weeks for 12 weeks. Treatment occurs in three steps: cleansing and peeling; suction to extract dead skin cells, sebum, and debris; and application of blue LED light. Acne severity was graded by investigators and by patients using the Global Acne Severity Score (GASS).ResultsThe proportion of patients with no acne or almost clear skin (GASS ≤1) at baseline versus final treatment increased from 20 to 65 percent per investigator assessment (p=0.0027), and from 5 to 55 percent per patient self-report (p=0.0016). At final treatment, more than 80 to 100 percent of both investigators and patients agreed or strongly agreed there was an improvement in skin appearance across multiple assessment parameters. Treatments were generally well tolerated.LimitationsDue to the nature of the treatment, blinding of neither investigators nor patients was feasible.ConclusionThe results presented here suggest that a series of six HydraFacial Clarifying Treatments improves overall skin appearance in patients with active acne.     

舒缓保湿修护霜在异维 A 酸软胶囊治疗痤疮中的皮肤保护作用

目的 观察舒缓保湿修护霜在异维A酸软胶囊治疗痤疮过程中的皮肤保护作用。方法 选择2020年1月-2021年3月我院皮肤科门诊收治的60例中度痤疮患者为研究对象,均系统使用异维A酸软胶囊口服治疗,治疗2周后随机分为观察组及对照组,各30例。观察组外用舒缓保湿修护霜,对照组外用氧化锌软膏,两组均继续接受同等剂量异维A酸软胶囊口服治疗,比较两组面部异常状态及不适症状评分、皮肤属性及角质层含水量,记录观察组满意度及不良反应发生情况。结果 观察组面部皮肤异常状态及自觉不适症状评分低于对照组（P＜0.05）;观察组面部主观皮肤属性评分高于对照组（P＜0.05）;观察组客观平滑度、水润度、柔韧性属性评分高于对照组（P＜0.05）;两组客观光泽度属性比较,差异无统计学意义（P＞0.05）;观察组皮肤角质层含水量高于对照组（P＜0.05）;观察组治疗满意度较高,未发生不良反应。结论 舒缓保湿修护霜可以缓解因异维A酸软胶囊治疗痤疮而产生的发红、干燥等皮肤不适症状,改善皮肤状态,且安全性及患者满意度较高。